Evidence map›Paper›PMID 30761545›Full record

ArticleMedical physics2019

Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for

Youngho Seo, Yoonsuk Huh, Shih-Ying Huang, J Miguel Hernandez-Pampaloni, Randall A Hawkins, W Clay Gustafson, Kieuhoa T Vo, Katherine K Matthay

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical physics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Simultaneous Imaging of Ga-DOTA-TATE and Lu-DOTA-TATE in Murine Models of Neuroblastoma.IEEE transactions on radiation and plasma medical sciences · 2023
    Article
  6. Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  7. Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Youngho SeoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
Yoonsuk HuhDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
Shih-Ying HuangDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
J Miguel Hernandez-PampaloniDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
Randall A HawkinsDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
W Clay GustafsonDepartment of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Kieuhoa T VoDepartment of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Katherine K MatthayDepartment of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.

Funding

Energy-independent single photon molecular imaging technologyR01EB026331 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CUI, YONGGANG, SEO, YOUNGHO · 2018 to 2022
$2.6M
Pretherapy 124I-MIBG Dosimetry for Planning 131I-MIBG Neuroblastoma TherapyR01CA154561 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEO, YOUNGHO · 2011 to 2016
$1.9M
NCI NIH HHS R01 CA154561NIBIB NIH HHS R01 EB026331
6 · The paper itself

Abstract

purposeRadiation dose calculated on tumors for radiopharmaceutical therapy varies significantly from tumor to tumor and from patient to patient. Accurate estimation of radiation dose requires multiple time point measurements using radionuclide imaging modalities such as SPECT or PET. In this report, we show our technical development of reducing the number of scans needed for reasonable estimation of tumor and normal organ dose in our pretherapy imaging and dosimetry platform of

methodsWe analyzed the simplest kinetic data, areas of two-time point data for five patients with neuroblastoma who underwent 3 or 4 times of

resultsThe areas of %IAs between data obtained from all the two-time points with time points 1 and 2 (day 0 and day 1), time points 2 and 3 (day 1 and day 2), and time points 1 and 3 (day 0 and day 2) showed reasonable correlation (Pearson's correlation coefficient |r| > 0.5) with not only tumor and organ TIACs but also tumor and organ absorbed doses. The tumor and organ doses calculated using %IA areas of time point 1 and time point 2 were our best fits at about 20% individual percent difference compared to doses calculated using 3 or 4 time points.

conclusionsWe could achieve reasonable accuracy of estimating tumor doses for subsequent radiopharmaceutical therapy using only the two-time point imaging sessions. Images obtained from these time points (within the 48-h after administration of radiopharmaceutical) were also viewed as useful for diagnostic reading. Although our analysis was specific to

Indexed as

3-IodobenzylguanidinePositron Emission Tomography Computed TomographyAdolescentAdultChildFeasibility StudiesFemaleHumansIodine RadioisotopesMaleNeuroblastomaRadiometryRadiotherapy DosageSafetyYoung Adult3-IodobenzylguanidineIodine-131Iodine RadioisotopesdosimetryMIBGneuroblastomaradionuclide therapytumor dosimetry

Identifiers

PMID30761545
PMCPMC6510622

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.